ArticleFrontiers in immunology2025
Serum creatinine to cystatin C ratio is a prognostic indicator in esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to explore the relationship between pretreatment serum creatinine to cystatin C ratio (CCR) and prognosis in patients with esophageal squamous cell carcinoma (ESCC) receiving neoadjuvant immunochemotherapy (NICT). Methods: Two hundred and two ESCC patients who received NICT were included in the current retrospective study. The restricted cubic spline displayed the non-linear relationship between prognosis and CCR. The association between overall survival (OS)/disease-free survival (DFS) and CCR was also investigated. Kaplan-Meier methods and Cox proportional hazard regression analyses were employed. Results: The connection between DFS/OS and CCR suggested that their interaction was non-linear. The restricted cubic spline (RCS) model identified 97.5 as the ideal cutoff point for CCR and divided it into 2 groups. Patients exhibiting low CCR demonstrated significantly worse 3-year DFS (48.5% vs. 74.3%, P<0.001) and OS (62.9% vs. 82.9%, P=0.001) compared to those with high CCR. The results indicated that CCR had prognostic significance for the ESCC cases stratified according to subgroup analyses. Compared to the low CCR group, subsequent multivariate analysis revealed that the high CCR group reduced the risk of recurrence by 56.0% (P=0.001) and the risk of death by 51.8% (P=0.013), respectively. Conclusion: The therapeutic efficacy of NICT for ESCC can be predicted by pretreatment CCR. Although the CCR may not have attained a very high quality, it still holds certain significance for clinical practice in ESCC patients undergoing NICT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.